Skip to content

Innoviva, Inc. INVA Long-Term Debt

Long-Term Debt at other companies

Pfizer logo
PfizerPFE
$60.57B+5.1%
Merck & Co. logo
Merck & Co.MRK
$49.1B+41.1%
Insmed logo
InsmedINSM
$542.22M-50.9%
Organon logo
OrganonOGN
$8.55B-4.3%
Royalty Pharma logo
Royalty PharmaRPRX
$8.58B+29.6%
Alkermes logo
AlkermesALKS

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.4B+9.7%
P/E3.5×
P/S4.1×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s long-term debt?
Innoviva, Inc. (INVA) reported long-term debt of $258.1M in Q1 2026.
How has Innoviva, Inc.'s long-term debt changed year-over-year?
Innoviva, Inc.'s long-term debt increased by 0.6% year-over-year, from $256.67M to $258.1M.
What is the long-term trend for Innoviva, Inc.'s long-term debt?
Over 5 years (2020 to 2025), Innoviva, Inc.'s long-term debt has grown at a -7.7% compound annual growth rate (CAGR), from $385.52M to $257.73M.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.